Receipt of glucocorticoid monotherapy among medicare beneficiaries with rheumatoid arthritis

Arthritis Care and Research

Volumn 66, Issue 10, 2014, Pages 1447-1455

  Yazdany, Jinoos ^a   Tonner, Chris ^a   Schmajuk, Gabriela ^a   Lin, Grace A ^a   Trivedi, Amal N ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; PREDNISONE; ANTIRHEUMATIC AGENT; GLUCOCORTICOID;

AGED; AMBULATORY CARE; ARTICLE; COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; FEMALE; HEALTH CARE QUALITY; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; ICD-9; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SOCIAL STATUS; UNITED STATES; AGE; ARTHRITIS, RHEUMATOID; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; DRUG COMBINATION; DRUG USE; INSURANCE; MEDICARE; MULTIVARIATE ANALYSIS; ORGANIZATION AND MANAGEMENT; PATIENT REFERRAL; PRESCRIPTION; SOCIOECONOMICS; STATISTICAL MODEL; TIME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHI-SQUARE DISTRIBUTION; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; ELIGIBILITY DETERMINATION; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; INSURANCE BENEFITS; LOGISTIC MODELS; MALE; MEDICARE PART D; MULTIVARIATE ANALYSIS; OFFICE VISITS; PHYSICIAN'S PRACTICE PATTERNS; QUALITY INDICATORS, HEALTH CARE; REFERRAL AND CONSULTATION; SOCIOECONOMIC FACTORS; TIME FACTORS; UNITED STATES;

EID: 84908544676     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22312     Document Type: Article

References (28)

1. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77-90.
2. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of diseasemodifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
3. National Committee for Quality Assurance. HEDIS and quality measurement. http://ncqa.org/tabid/59/default.aspx.
4. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
5. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284:984-92.
6. Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying antirheu-matic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011;305:480-6.
7. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007;57:928-34.
8. Lee SJ, Kremer J, Kavanaugh A, for the Consortium of Rheumatology Researchers of North America (CORRONA). Treatment disparity related to race/ethnicity and education in rheumatoid arthritis patients: comment on the article by Constantinescu et al [letter]. Arthritis Rheum 2009;61:1141-2.
9. US Department of Health and Human services, Health Resources and Services Administration, Bureau of Health Professions. Area Resource File (ARF). 2009-2012.
10. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43: 1130-9.
11. Bernatsky S, Lix L, Hanly JG, Hudson M, Badley E, Peschken C, et al. Surveillance of systemic autoimmune rheumatic diseases using administrative data. Rheumatol Int 2011;31: 549-54.
12. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J 2009; 16:183-8.
13. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicutto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. COPD 2009;6: 388-94.
14. Solomon DH, Yelin E, Katz JN, Lu B, Shaykevich T, Ayanian JZ. Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey. Arthritis Res Ther 2013;15:R43.
15. Garneau KL, Iversen MD, Tsao H, Solomon DH. Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement. Arthritis Res Ther 2011;13: R189.
16. Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken) 2012;64:184-9.
17. Jong M, Kraishi M. A comparative study on the utility of telehealth in the provision of rheumatology services to rural and northern communities. Int J Circumpolar Health 2004;63: 415-21.
18. Harrington JT, Walsh MB. Pre-appointment management of new patient referrals in rheumatology: a key strategy for improving health care delivery. Arthritis Rheum 2001;45: 295-300.
19. Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006;65:1226-9.
20. Bathon JM, Fleischmann RM, van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006;33:234-43.
21. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, for the Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007;57:679-85.
22. Hirshberg B, Muszkat M, Schlesinger O, Rubinow A. Safety of low dose methotrexate in elderly patients with rheumatoid arthritis. Postgrad Med J 2000;76:787-9.
23. Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewe R, et al. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:995-1003.
24. Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, et al. Validation of rheumatoid arthritis diagnoses in health care utilization data. Arthritis Res Ther 2011;13:R32.
25. Ng B, Aslam F, Petersen NJ, Yu HJ, Suarez-Almazor ME. Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study. Arthritis Care Res (Hoboken) 2012;64:1490-6.
26. Schmajuk G, Yazdany J. Underestimation of the reliability of codes for rheumatoid arthritis within administrative data: comment on the article by Ng et al [letter]. Arthritis Care Res (Hoboken) 2013;65:835-6.
27. Gabriel SE. The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37:821-3.
28. Arday SL, Arday DR, Monroe S, Zhang J. HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev 2000;21:107-16.